求助文献一篇

【作者(必填)】
Nguyen C, Cheng-Lai A.
【文题(必填)】
The Polypill: A Proposed Global Solution to Cardiovascular Disease.【年份(必填)】
Cardiol Rev. 2012 Sep 26. [Epub ahead of print]
【全文链接或数据库名称(选填)】http://www.ncbi.nlm.nih.gov/pubmed/23018668

只能找到这些
Author Nguyen, Caroline Pharm.D.; Cheng-Lai, Angela Pharm.D., BCPS *

Institution From the Depts. Of Pharmacy, Cedars Sinai Medical Center, Los Angeles, Ca., and (*)Montefiore Medical Center, Bronx, NY.

Title The Polypill: A Proposed Global Solution to Cardiovascular Disease.[Miscellaneous Article]

Source Cardiology in Review.

Status Publish Ahead of Print, POST ACCEPTANCE, 26 September 2012

Local Message Title held by Glasgow University Library - see Library Holdings

Abstract Despite groundbreaking advances in healthcare, cardiovascular disease (CVD) remains the leading cause of death and disability worldwide, making it one of the most pressing global health issues to face the modern world. In 2002, Wald and Law proposed the concept of the polypill as a potential solution to this global health epidemic. The polypill represents a powerhouse pill that would consist of a combination of several key medications commonly prescribed for CVD prevention, such as a statin, diuretic, beta blocker, or ACE inhibitor, in one. It was suggested that it could be a novel, tactical measure in the approach to CVD prevention in that it greatly simplifies the healthcare delivery system. Not only does it increase medication compliance for those currently receiving healthcare, but it also has the potential to access those in underserved healthcare sectors of the world, primarily low- and middle- income countries, which have been identified as areas of highest CVD risk. A major drawback of the polypill is that there are limited data demonstrating its safety and efficacy in the prevention of CV morbidity and mortality. Thus far, research shows that the polypill has promise but needs to be approached with a few considerations, such as desired target patient population and formulation. This paper will examine the published and ongoing studies associated with the polypill, outline the advantages and disadvantages of utilizing the polypill as a global CVD prevention strategy, and discuss the design and availability of the polypill in the United States.

(C) 2012 Lippincott Williams & Wilkins, Inc.

Author Keywords polypill; polycap; fixed dose compound; red heart pill; cardiovascular disease; global healthcare.

Language English.

Document Type New Therapy Update: PDF Only.

Journal Subset Clinical Medicine.

ISSN 1061-5377

NLM Journal Code dej, 9304686

DOI Number 10.1097/CRD.0b013e3182755429